Enobia Pharma is focused on developing ENB-0040, an enzyme replacement therapy (ERT) for hypophosphatasia, a rare and potentially life‑threatening genetic bone disorder with no approved therapy. The company has completed two 6‑month clinical studies: a Phase I/II study begun in October 2008 in infants and young children with life‑threatening hypophosphatasia, and a Phase II study in children aged 5–12. Enobia is in Phase IIb clinical development and is enrolling additional infants and children under age 5. ENB-0040 manufactured at commercial scale is being used in the clinical trials. The company intends to use the proceeds from the financing to fund ongoing development of ENB-0040. The company is based in Montreal, Canada.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2011